EUVIMEDOpdag EUVIMED
VergleichsstudieBeobachtungsstudie

Long‐Term Clinical Outcomes of Biodegradable‐ Versus Durable‐Polymer‐Coated Everolimus‐Eluting Stents in Real‐World Post‐Marketing Study

Waiel Abusnina, Brian C Case, Cheng Zhang, Kalyan R Chitturi, Vaishnavi Sawant, Abhishek Chaturvedi, Dan Haberman, Lior Lupu, Jospeh A Sutton, Syed W Ali, Teshome Deksissa, Shreejana Pokharel and 7 more

Catheterization and Cardiovascular Interventions · 2025

DOI: 10.1002/ccd.31292 ↗

At a glance

Vergleichsstudie in Catheterization and Cardiovascular Interventions, 2025. Written by Waiel Abusnina and 18 co-authors. Institution: Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia, USA. Major MEDLINE topics: Drug-Eluting Stents, Absorbable Implants, Everolimus, Percutaneous Coronary Intervention. Cited 1 times so far (Crossref); 25 references. Funded by: Financial support was provided by the Boston Scientific Corporation., Boston Scientific Corporation.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Long‐term clinical data on biodegradable‐polymer (BP) drug‐eluting stents (DES) are limited. The objective of this study was to assess the long‐term safety and efficacy of the BP‐DES SYNERGY compared to XIENCE V, a durable‐polymer (DP)‐DES.

Methods

We compared patients treated with BP‐DES or DP‐DES at our center from 2008 to 2020. The primary outcome was major adverse cardiac events (MACE), defined as the composite of all‐cause death, Q‐wave myocardial infarction (MI), and target vessel revascularization (TVR). Secondary endpoints were all‐cause death, Q‐wave MI, target lesion revascularization (TLR), and stent thrombosis (ST).

Results

A total of 4255 patients underwent propensity‐score matching, and 380 patients from each cohort were matched. There was no significant difference between BP‐DES and DP‐DES concerning MACE (5‐year estimates: 21.6% vs. 26.6%, log‐rank p = 0.259). Furthermore, there was no difference in the TLR rate (5‐year estimates: 7.3% vs. 8.6%, log‐rank p = 0.781). All‐cause death (5‐year estimates: 13.6% vs. 12.9%, log‐rank p = 0.72) and Q‐wave MI (5‐year estimates: 0.53% vs. 1.7%, log‐rank p = 0.427) were also comparable between the two groups. Of note, the rate of very late ST was very low and similar between the groups (5‐year estimates: 0.26% vs. 0.64%, log‐rank p = 0.698).

Conclusion

BP‐DES and DP‐DES demonstrate similar safety and efficacy at 5‐year follow‐up. Both can be used for the effective treatment of coronary artery disease.

Subjects

MeSH terms (MEDLINE)

Drug-Eluting StentsAbsorbable ImplantsEverolimusPercutaneous Coronary InterventionCoronary Artery DiseasePolymersCardiovascular AgentsHumansMaleFemaleAgedProsthesis DesignTime FactorsTreatment OutcomeMiddle AgedRisk FactorsRetrospective StudiesRisk AssessmentProduct Surveillance, Postmarketing

Author keywords

biodegradable polymercoronary artery diseasedrug‐eluting stentdurable polymereverolimus‐eluting stent

Substances

EverolimusPolymersCardiovascular Agents

Authors and institutions

  • Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia, USA.

ORCID profiles: Lowell F Satler, Ron Waksman

Funding

  • Financial support was provided by the Boston Scientific Corporation.
  • Boston Scientific Corporation

Cite

APA

Abusnina, W., Case, B. C., Zhang, C., Chitturi, K. R., Sawant, V., Chaturvedi, A., Haberman, D., Lupu, L., Sutton, J. A., Ali, S. W., Deksissa, T., Pokharel, S., Ozturk, S. T., Margulies, A., Ben-Dor, I., Hashim, H. D., Satler, L. F., Garcia-Garcia, H. M., & Waksman, R. (2025). Long‐Term Clinical Outcomes of Biodegradable‐ Versus Durable‐Polymer‐Coated Everolimus‐Eluting Stents in Real‐World Post‐Marketing Study. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31292

Vancouver

Abusnina W, Case BC, Zhang C, Chitturi KR, Sawant V, Chaturvedi A, et al. Long‐Term Clinical Outcomes of Biodegradable‐ Versus Durable‐Polymer‐Coated Everolimus‐Eluting Stents in Real‐World Post‐Marketing Study. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.31292

BibTeX
@article{Abusnina2025,
  author = {Abusnina, Waiel and Case, Brian C and Zhang, Cheng and Chitturi, Kalyan R and Sawant, Vaishnavi and Chaturvedi, Abhishek and Haberman, Dan and Lupu, Lior and Sutton, Jospeh A and Ali, Syed W and Deksissa, Teshome and Pokharel, Shreejana and Ozturk, Sevket T and Margulies, Adrian and Ben-Dor, Itsik and Hashim, Hayder D and Satler, Lowell F and Garcia-Garcia, Hector M and Waksman, Ron},
  title = {Long‐Term Clinical Outcomes of Biodegradable‐ Versus Durable‐Polymer‐Coated Everolimus‐Eluting Stents in Real‐World Post‐Marketing Study},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2025},
  doi = {10.1002/ccd.31292}
}
Start for free →